Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890037 | 0.79 | GPR84 (0.67) | GPR84NPC1RAB9AHPGDTP53 | |
| SCHEMBL15457569 | 0.78 | PKM (0.53) | PKMGPR84SMN1; SMN2HPGDMAPT | |
| SCHEMBL5552693 | 0.78 | SCN9A (0.55) | PKMRAB9APOLBDDB1CRBN | |
| SCHEMBL18931726 | 0.78 | PKM (0.53) | PKMSMN1; SMN2HPGDMAPTPOLB | |
| SCHEMBL1908212 | 0.78 | MEN1 (0.66) | PKMGPR84SMN1; SMN2MAPTPOLB | |
| SCHEMBL25350548 | 0.75 | PKM (0.68) | PKMSMN1; SMN2HPGDGAAMAPT | |
| SCHEMBL17422233 | 0.75 | POLB (0.50) | PKMGPR84NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1733432 | 0.73 | GPR84 (0.58) | PKMGPR84MAPTPOLBLMNA | |
| SCHEMBL6261877 | 0.73 | FABP4 (0.53) | PKMRAB9AHPGDPOLB | |
| SCHEMBL12158279 | 0.73 | PKM (0.49) | PKMGPR84NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-02 | — | — | US | disclosed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3759082-B1 | PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL | PROCOS SPA (IT) | 2022-04-20 | — | — | EP | disclosed |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | PROCOS S.P.A. (IT) | 2021-06-08 | — | — | US | disclosed |
| US-4399142-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-08-16 | — | — | US | disclosed |
| EP-0074229-A1 | Triazole gastric anti-secretory agents | PFIZER INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| US-4374251-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-02-15 | — | — | US | disclosed |
| US-4341787-A | ANTIHISTAMINES; ANTISECRETORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1982-07-27 | — | — | US | disclosed |
| US-4282221-A | Pharmacologically active compounds to inhibit H-2 histamine receptors | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-08-04 | — | — | US | disclosed |
| US-4260744-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-04-07 | — | — | US | disclosed |
| US-4181730-A | ANTISECRETORY AGENTS, IMIDAZOLYALKYLIMIDAZOLINONES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-01 | — | — | US | disclosed |
| US-4153793-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
| US-4104381-A | HISTAMINE INHIBITORS, ((IMIDAZOLYLALKYL)AMINO)THIADIAZINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | disclosed |
| US-4005205-A | PYRIMIDINE COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | PKM 1975/4885GPR84 233/4885NPC1 2635/4885 |
| US-11028057-B2 | Process for the synthesis of 6-chloromethyluracil | DHPS, TPMT, MPST | PKM 1409/4885GPR84 3696/4885NPC1 4551/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | PKM 4689/4885GPR84 1641/4885NPC1 185/4885 |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, ADCYAP1R1 | PKM 1708/4885GPR84 329/4885NPC1 2334/4885 |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | PKM 3697/4885GPR84 80/4885NPC1 1009/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | PKM 4689/4885GPR84 1641/4885NPC1 185/4885 |
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | TUBB, TUBB1, TUBA1C | PKM 1089/4885GPR84 4106/4885NPC1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.